Novel Endoglycosidase Derivatives Treating Diseases of the Adaptive Immune System
Application
Protein-based therapeutics for the treatment of IgG-mediated diseases.
Key Benefits
A new class of endoglycosidases for the treatment of IgG-mediated diseases.
Four novel compounds have been developed that exhibited robust in vitro activity.
Potential to become first-in-class medications for dysregulation of the adaptive immune system,...
Published: 2/13/2025
Contributor(s): Eric Sundberg, Diego Sastre, Jonathan Du, Jeffrey Ravetch, Stylianos Bournazos
|
HDAC Inhibitors for Managing Vascular Conditions and Diabetic Peripheral Neuropathies
Application
Treatment of diabetic neuropathy using epigenetic modulators, histone deacetylase inhibitors (HDACis), to ameliorate or prevent vascular conditions and neuropathic pains by nerve damages.
Key Benefits
Reverses or protects against diabetes-induced nerve damages by direct injection of HDACi.
Relatively low regulatory risk because many...
Published: 2/13/2025
Contributor(s): Young-Sup Yoon, Ji Woong (Jay) Han, Hyunsuk Shim
|
Novel Inhibitors of NOX2/ROS
Applications
Novel therapeutics for treatment of various inflammatory airway conditions including chronic obstructive pulmonary disease (COPD).
Key Benefits
NOX2/ROS inhibitors have potential for use in a wide variety of clinical indications.
Current treatments are weakly effective or provide only symptomatic relief for inflammatory airway diseases.
Technical...
Published: 2/13/2025
Contributor(s): Thota Ganesh, John David Lambeth, Susan Smith, Aiming Sun
|
Functional Restoration of Diabetic Bone Marrow-Derived Cells
Application
Methods for restoration of diabetic bone marrow cell function for cell based therapy, using pre-existing molecules and their derivatives.
Key Benefits
Ability to "reactivate" diabetic bone marrow-derived stem or progenitor cells which also include peripheral blood cells such as endothelial progenitor cells.
Cells are more...
Published: 2/13/2025
Contributor(s): Young-Sup Yoon, Ji Woong (Jay) Han
|